Fagron NV (ARSUF)
23.50
0.00 (0.00%)
USD |
OTCM |
Dec 10, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.726B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 17.32% |
| Valuation | |
| PE Ratio | 18.40 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.716 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 49.81% |
Profile
| Fagron NV engages in the development, marketing, and distribution of healthcare products and services. It operates through the following segments: Essentials, Brands, and Compounding Services. The Essential segment focuses on supplying raw materials to community and hospital pharmacies for pharmaceutical compounding. The Brands segment is involved in developing and producing semi-finished products and vehicles, such as emulsions, powder mixtures, creams, and other excipients, as well as total concepts and equipment for pharmaceutical compounding. The Compounding Services segment offers community and hospital pharmacies with ready-to-use non-sterile compounded medicine in those countries where it is permitted. The company was founded in 1990 and is headquartered in Nazareth, Belgium. |
| URL | http://www.fagron.com |
| Investor Relations URL | N/A |
| HQ State/Province | Flemish Region |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Next Earnings Release | Feb. 12, 2026 |
| Last Earnings Release | Jul. 31, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 21, 2024 |
Ratings
Profile
| Fagron NV engages in the development, marketing, and distribution of healthcare products and services. It operates through the following segments: Essentials, Brands, and Compounding Services. The Essential segment focuses on supplying raw materials to community and hospital pharmacies for pharmaceutical compounding. The Brands segment is involved in developing and producing semi-finished products and vehicles, such as emulsions, powder mixtures, creams, and other excipients, as well as total concepts and equipment for pharmaceutical compounding. The Compounding Services segment offers community and hospital pharmacies with ready-to-use non-sterile compounded medicine in those countries where it is permitted. The company was founded in 1990 and is headquartered in Nazareth, Belgium. |
| URL | http://www.fagron.com |
| Investor Relations URL | N/A |
| HQ State/Province | Flemish Region |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Next Earnings Release | Feb. 12, 2026 |
| Last Earnings Release | Jul. 31, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 21, 2024 |